In this study, we demonstrate that the level of expression of CSF-1R within the lymphoid aggregates induced by GVAX affects the tumor immune microenvironment; high CSF-1R expression is associated with an immunosuppressive environment in patients who received GVAX. Here, CSF1R is linked to neoplasm.